Why the study?
Direct oral factor Xa inhibitors interfere with lupus anticoagulant assays, challenging the diagnosis of antiphospholipid syndrome in treated patients.
Does the DOAC Filter effectively remove FXa inhibitors from plasma samples without affecting lupus anticoagulant testing?
Does the DOAC Filter effectively remove FXa inhibitors from plasma samples without affecting lupus anticoagulant testing?
The DOAC Filter effectively removes rivaroxaban and apixaban from plasma samples, preventing their interference with lupus anticoagulant testing.
Answers are grounded in this paper and cite their sources.
DOAC Filter may enable LA testing during FXa inhibitor therapy; leaves open validation in larger APS cohorts before adoption.
Background: Direct oral factor Xa (FXa) inhibitors interfere with lupus anticoagulant (LA) assays challenging antiphospholipid syndrome diagnosis in treated patients. We evaluated a new device, called DOAC Filter, and its usefulness in this setting. It is a single-use filtration cartridge in which FXa inhibitor compounds are trapped by non-covalent binding while plasma is filtered through a solid phase. Patient samples were analyzed before and after filtration: 38 rivaroxaban, 41 apixaban, and 68 none. Anticoagulant plasma concentrations were measured using specific anti-Xa assays and HPLC-MS/MS. LA testing was performed using dilute Russell Viper Venom Time (dRVVT) and Silica Clotting Time (SCT). Baseline median [min–max] concentrations were 64.8 [17.6; 311.4] for rivaroxaban and 92.1 ng/mL [37.1; 390.7] for apixaban (HPLC-MS/MS). They were significantly correlated with anti-Xa assay results ( r = 0.98 and r = 0.94, respectively). dRVVT was positive in 92% rivaroxaban and 72% apixaban and SCT in 28 and 41% of samples, respectively. Post-filtration, median % of neutralization was 100% with rivaroxaban and apixaban concentrations of, respectively, <2 [<2–2.4] and <2 ng/mL [<2–9.6] using HPLC-MS/MS. No significant effect of DOAC Filter was observed on LA testing in controls ( n = 31) and LA-positive ( n = 37) non-anticoagulated samples. dRVVT and SCT remained positive in, respectively, 16 and 8% of rivaroxaban and 41 and 18% of apixaban samples. DOAC Filter would be an easy-to-use device allowing FXa inhibitor removal from plasma samples, limiting their interference with LA testing in treated patients.
No takes yet. Share an insight, caveat, or question.
Farkh et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: